These innovative compounds represent a significant leap in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://ambersyqo604150.qowap.com/98076337/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide